ClinicalTrials.gg
Not yet recruitingNCT07568964Updated May 6, 2026

Evaluation of Probiotics' Effect on Atrial Fibrillation Recurrence in Patients Undergoing Cardioversion

An interventional study of Anticoagulant Therapy and Probiotics capsules in Atrial Fibrillation (AF), sponsored by Ain Shams University. Not yet recruiting at 1 site in Egypt. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Atrial Fibrillation by Ain Shams University — 3 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · Ain Shams University.

Started
2026
with 1 other
No phase
3 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Atrial Fibrillation by Ain Shams University, this one is one of 2 that started in 2026, is one of 3 with no phase, and was the 11th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 11 studies in Atrial Fibrillation by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Atrial Fibrillation by Ain Shams University, or all of them as a file.
02

Study summary

The aim of this clinical study is to evaluate the efficacy and tolerability of probiotics on atrial fibrillation recurrence.

Read the detailed description

Assessment of AF recurrence: Early AF recurrence is defined as relapse into AF within 1 week following successful cardioversion and AF recurrence through the study's 12-week follow-up.

Patients and Methods Design: Prospective, randomized, open label, controlled clinical trial

Patients: A total of 56 AF patients undergoing cardioversion will be randomly enrolled into one of 2 arms:

  1. Group 1 (Control group) (n=28): AF patients undergoing cardioversion who will receive the standard of care
  2. Group 2 (Probiotic group) (n = 28): AF patients undergoing cardioversion who will receive the standard of care in addition to probiotics DAILY orally administered (Probiotics 25 billion) after cardioversion for 12 weeks.

Groups (1 \& 2) will be subjected to cardioversion on admission according to standard protocols and criteria.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male aged 40 years or above with less than 40
  2. Persistent AF patients directly after cardioversion

Exclusion criteria

Exclusion Criteria:

  1. History of probiotic supplementation in the previous 6 weeks
  2. diseases
  3. Ongoing treatment with therapies
  4. Active Infection
  5. Pregnant or breast-feeding patients
  6. Active participation in another clinical study
  7. History of or known allergy or intolerability to the study medications
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Experimental: Control group

    28 AF patients undergoing cardioversion who will receive standard of care

    Drug: Anticoagulant Therapy

  • Experimental
    Experimental: Probiotic group

    28 AF patients undergoing cardioversion who will receive the standard of care in addition to Probiotics 25 billion daily orally, after cardioversion for 12 weeks

    Drug: Anticoagulant Therapy · Drug: Probiotics capsules

Interventions

  • DrugAnticoagulant Therapy

    Drug: The standard of care for AF management directly following cardioversion Include anticoagulant therapy for at least 4 weeks, rate control therapy, rhythm control therapy, or both as per clinical and guideline decisions.

    Also known as: Rate Control Therapy, Rhythm Control Therapy

  • DrugProbiotics capsules

    Probiotics at a of dose 25 billion / 1 capsule will be orally administered daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Atrial Fibrillation Recurrence

    Time frame: 7 days

Secondary outcomes

  1. Atrial Fibrillation Recurrence

    Time frame: 12 weeks

07

Study locations

1 site
  • Ain Shams University's Hospital
    Cairo, Egypt
08

References and documents

Publications

  • Brar AS, Vemula SL, Yanamaladoddi V, Sodhi S, Hatwal J, Sohal A, Batta A. Impact of gut microbiome on atrial fibrillation: Mechanistic insights and future directions in individualized medicine. World J Cardiol. 2025 Jun 26;17(6):107386. doi: 10.4330/wjc.v17.i6.107386. PubMed 40575430 ↗
  • Chen J, Wang Y, Wang K, Mei Z, Wang L. Exploring the Axis of Gut Microbiota-Inflammatory Cytokine-Atrial Fibrillation in the Pathogenesis of Atrial Fibrillation. J Cell Mol Med. 2025 Feb;29(3):e70379. doi: 10.1111/jcmm.70379. PubMed 39930552 ↗
  • Drapkina OM, Yafarova AA, Kaburova AN, Kiselev AR. Targeting Gut Microbiota as a Novel Strategy for Prevention and Treatment of Hypertension, Atrial Fibrillation and Heart Failure: Current Knowledge and Future Perspectives. Biomedicines. 2022 Aug 19;10(8):2019. doi: 10.3390/biomedicines10082019. PubMed 36009566 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for May 2027, 12 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 12 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
May 6, 2026
StartEst.
May 10, 2026
Primary completionEst.
May 10, 2027
CompletionEst.
Sep 1, 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07568964
Responsible party
Sarah Mostafa Mostafa Abdelfatah Raesah (Teaching Assistant and Researcher in Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University., Ain Shams University) — Principal investigator
First posted
May 6, 2026
Start date
May 10, 2026 (estimated)
Primary completion
May 10, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
May 6, 2026

Study contacts

Sarah M. Raesah
Contact
sara.mostafa18@pharma.asu.edu.eg
+201018585869

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion